173 related articles for article (PubMed ID: 31649038)
1. Unique
Serra S; Capo-Chichi JM; McCarthy AJ; Sabatini P; Chetty R
J Clin Pathol; 2020 May; 73(5):291-295. PubMed ID: 31649038
[TBL] [Abstract][Full Text] [Related]
2. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
3. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
4. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
5. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
6. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
7. Routine Molecular Analysis for Lynch Syndrome Among Adenomas or Colorectal Cancer Within a National Screening Program.
Goverde A; Wagner A; Bruno MJ; Hofstra RMW; Doukas M; van der Weiden MM; Dubbink HJ; Dinjens WNM; Spaander MCW
Gastroenterology; 2018 Nov; 155(5):1410-1415. PubMed ID: 30063919
[TBL] [Abstract][Full Text] [Related]
8. A Novel Germline
Klančar G; Blatnik A; Šetrajčič Dragoš V; Vogrič V; Stegel V; Blatnik O; Drev P; Gazič B; Krajc M; Novaković S
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32197529
[TBL] [Abstract][Full Text] [Related]
9. MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case.
Kientz C; Prieur F; Clemenson A; Joly MO; Stachowicz ML; Auclair J; Attignon V; Schiappa R; Wang Q
Fam Cancer; 2020 Jan; 19(1):11-14. PubMed ID: 31745674
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair deficiency in Lynch syndrome-associated colorectal adenomas is more prevalent in older patients.
Tanaka M; Nakajima T; Sugano K; Yoshida T; Taniguchi H; Kanemitsu Y; Nagino M; Sekine S
Histopathology; 2016 Aug; 69(2):322-8. PubMed ID: 26826556
[TBL] [Abstract][Full Text] [Related]
11. Integrating Tumor Sequencing Into Clinical Practice for Patients With Mismatch Repair-Deficient Lynch Syndrome Spectrum Cancers.
Dixon K; Asrat MJ; Bedard AC; Binnington K; Compton K; Cremin C; Heidary N; Lohn Z; Lovick N; McCullum M; Mindlin A; O'Loughlin M; Petersen T; Portigal-Todd C; Scott J; St-Martin G; Thompson J; Turnbull R; Mung SW; Hong Q; Bezeau M; Bosdet I; Tucker T; Young S; Yip S; Aubertin G; Blood KA; Nuk J; Sun S; Schrader KA
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00397. PubMed ID: 34397043
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
13. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
15. PMS2 involvement in patients suspected of Lynch syndrome.
Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
[TBL] [Abstract][Full Text] [Related]
16. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.
Shia J; Klimstra DS; Nafa K; Offit K; Guillem JG; Markowitz AJ; Gerald WL; Ellis NA
Am J Surg Pathol; 2005 Jan; 29(1):96-104. PubMed ID: 15613860
[TBL] [Abstract][Full Text] [Related]
17. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
[TBL] [Abstract][Full Text] [Related]
18. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry.
Walsh MD; Buchanan DD; Pearson SA; Clendenning M; Jenkins MA; Win AK; Walters RJ; Spring KJ; Nagler B; Pavluk E; Arnold ST; Goldblatt J; George J; Suthers GK; Phillips K; Hopper JL; Jass JR; Baron JA; Ahnen DJ; Thibodeau SN; Lindor N; Parry S; Walker NI; Rosty C; Young JP
Mod Pathol; 2012 May; 25(5):722-30. PubMed ID: 22322191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]